

Anlotib

Anlotinib Hydrochloride INN



Composition

Anlotib 12 Capsule: Each capsule contains Anlotinib Hydrochloride INN eqv. to Anlotinib 12 mg.

Pharmacology

Anlotinib HCl is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit.

Indications

Anlotinib hydrochloride is indicated for the treatment of Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of Anlotinib in patients with advanced NSCLC.

Dosage and Administration

Anlotinib hydrochloride capsule 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).

Adverse Reactions

- Perforations and Fistula
- Hemorrhage
- Thromboembolic Events
- Impaired Wound Healing
- Hypertension and Hypertensive Crisis
- Osteonecrosis of the Jaw
- Diarrhea
- Palmar-Plantar Erythrodysesthesia
- Proteinuria
- Reversible Posterior Leukoencephalopathy Syndrome

Contraindications

None.

Use in Pregnancy

The limited human data on use of Anlotinib Hydrochloride in pregnant women are not sufficient to evaluate a drug-associate risk for major birth defects or miscarriage. Based on animal studies, Anlotinib has the potential to adversely affect a developing fetus therefore contraindicated during pregnancy.

Lactation

Advise not to breastfeed.

Storage

Do not store above 25°C. Protect from light. Keep out of reach of children.

Packaging

Anlotib 12 Capsule: Each HDPE container of Anlotib 12 contains 21's capsules, a silica gel desiccant and polyester coil with a child resistant closure.

Manufactured by:

ZISKA **Ziska Pharmaceuticals Ltd.**
Kaliakoir, Gazipur, Bangladesh

Version: 00

P-3499